Mirabegron Zentiva

Mirabegron, the active ingredient in Mirabegron Zentiva, is a Beta‑3 adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adults.

GNH USA supplies Mirabegron Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Mirabegron is a β3‑adrenergic receptor agonist used in the management of overactive bladder and related urinary symptoms. - Overactive bladder: improves bladder storage capacity and reduces urgency episodes. - Urinary urgency: lessens the frequency of sudden urges to void. - Urinary frequency: decreases daytime voiding episodes. - Urge incontinence: reduces episodes of involuntary leakage.

Adverse reactions reported with Mirabegron Zentiva are categorized by frequency.

Common Side Effects: - Hypertension: increase in blood pressure observed in some patients. - Headache: mild to moderate headache may occur. - Nasopharyngitis: inflammation of the nasal passages and throat. - Constipation: reduced bowel movements reported.

Serious or Rare Side Effects: - Acute urinary retention: inability to void requiring medical intervention. - Severe hypertension: marked rise in blood pressure needing urgent care. - Tachycardia: rapid heart rate that may be symptomatic. - Angioedema or allergic reaction: swelling of face, lips or airway.

When prescribing Mirabegron Zentiva, clinicians should observe the following precautions. - Monitor blood pressure: check regularly due to risk of hypertension. - Assess renal function: evaluate before initiation and adjust if impaired. - Evaluate hepatic function: use caution in patients with severe liver disease. - Review concomitant medications: avoid strong CYP2D6 inhibitors and potent CYP3A4 inducers. - Store at ambient temperature: keep below 25°C, in the original pack, protect from moisture.

Mirabegron may interact with other medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase Mirabegron exposure. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Co‑administration with other β3‑adrenergic agonists: additive pharmacologic effect.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effect when blood pressure falls. - Antihypertensive agents: monitor for additive blood‑pressure lowering. - NSAIDs: may increase risk of renal impairment, especially in susceptible patients.